Dr. Schultz has more than 35 years of experience in pharmaceutical and medical device development. He is the President and CEO of Sollievo Pharmaceuticals, Inc.
Dr. Schultz previously served as President and Chief Operating Officer of REVA Medical, Inc., a San Diego-based medical device company. From 2003 to 2017 he was responsible for converting in- licensed drugs and polymers into fully biodegradable, radiopaque cardiovascular stents and drug delivery products. REVA’s first commercialized product, Fantom®, using proprietary and highly unique technology, gained CE Mark approval in 2017. Dr. Schultz built and led a dynamic team of scientists, engineers, operations, and administrative professionals.
During his tenure, REVA raised $250 million from a range of sources, including a successful IPO listing in Australia in 2010.
Prior to REVA, Dr. Schultz held executive and research positions at Dura Pharmaceuticals and 3M Pharmaceuticals, where he spearheaded development and commercialization of dry powder and non-CFC inhalers.
Dr. Schultz’s expertise includes technical, business development, and executive leadership in the areas of conventional drug products, aerosol delivery, drug development, and cardiovascular devices. His expertise in early stage technology development has led to a passionate ability to accelerate progress on limited time and budgets.
Dr. Schultz received his BS in Pharmacy and PhD. in pharmaceutics from the University of Minnesota.
Copyright © 2021 Sollievo Pharmaceuticals - All Rights Reserved.
Powered by Captjur